<SEC-DOCUMENT>0000947871-24-000751.txt : 20240912
<SEC-HEADER>0000947871-24-000751.hdr.sgml : 20240912
<ACCEPTANCE-DATETIME>20240912165636
ACCESSION NUMBER:		0000947871-24-000751
CONFORMED SUBMISSION TYPE:	144
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20240912
DATE AS OF CHANGE:		20240912

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Chemomab Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001534248
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				813676773
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		144
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	001-38807
		FILM NUMBER:		241295561

	BUSINESS ADDRESS:	
		STREET 1:		KIRYAT ATIDIM, BUILDING 7
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6158002
		BUSINESS PHONE:		972-77-331-0156

	MAIL ADDRESS:	
		STREET 1:		KIRYAT ATIDIM, BUILDING 7
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6158002

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Anchiano Therapeutics Ltd.
		DATE OF NAME CHANGE:	20180906

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BioCancell Ltd.
		DATE OF NAME CHANGE:	20111104

REPORTING-OWNER:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OrbiMed Israel GP Ltd.
		CENTRAL INDEX KEY:			0001569590
		ORGANIZATION NAME:           	
		IRS NUMBER:				980697983
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		144

	BUSINESS ADDRESS:	
		STREET 1:		89 MEDINAT HAYEHUDIM STREET, 11TH FLOOR
		CITY:			HERZLIYA
		STATE:			L3
		ZIP:			46766
		BUSINESS PHONE:		212-739-6400

	MAIL ADDRESS:	
		STREET 1:		601 LEXINGTON AVENUE, 54TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022-4629
</SEC-HEADER>
<DOCUMENT>
<TYPE>144
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>144</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: OrbiMed Israel GP Ltd. -->
          <cik>0001569590</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <issuerInfo>
      <issuerCik>0001534248</issuerCik>
      <issuerName>Chemomab Therapeutics Ltd.</issuerName>
      <secFileNumber>001-38807</secFileNumber>
      <issuerAddress>
        <com:street1>Kiryat Atidim</com:street1>
        <com:street2>Building 7</com:street2>
        <com:city>Tel Aviv</com:city>
        <com:stateOrCountry>L3</com:stateOrCountry>
        <com:zipCode>6158002</com:zipCode>
      </issuerAddress>
      <issuerContactPhone>972-77-331-0156</issuerContactPhone>
      <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>OrbiMed Israel Partners Limited Partnership</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
      <relationshipsToIssuer>
        <relationshipToIssuer>Owner</relationshipToIssuer>
      </relationshipsToIssuer>
    </issuerInfo>
    <securitiesInformation>
      <securitiesClassTitle>American Depositary Shares</securitiesClassTitle>
      <brokerOrMarketmakerDetails>
        <name>Morgan Stanley</name>
        <address>
          <com:street1>1585 Broadway</com:street1>
          <com:city>New York</com:city>
          <com:stateOrCountry>NY</com:stateOrCountry>
          <com:zipCode>10036</com:zipCode>
        </address>
      </brokerOrMarketmakerDetails>
      <noOfUnitsSold>500000</noOfUnitsSold>
      <aggregateMarketValue>1015000.00</aggregateMarketValue>
      <noOfUnitsOutstanding>18508057</noOfUnitsOutstanding>
      <approxSaleDate>09/12/2024</approxSaleDate>
      <securitiesExchangeName>Nasdaq Stock Market</securitiesExchangeName>
    </securitiesInformation>
    <securitiesToBeSold>
      <securitiesClassTitle>American Depositary Shares</securitiesClassTitle>
      <acquiredDate>03/16/2021</acquiredDate>
      <natureOfAcquisitionTransaction>Merger</natureOfAcquisitionTransaction>
      <nameOfPersonfromWhomAcquired>Issuer</nameOfPersonfromWhomAcquired>
      <isGiftTransaction>N</isGiftTransaction>
      <amountOfSecuritiesAcquired>500000</amountOfSecuritiesAcquired>
      <paymentDate>03/16/2021</paymentDate>
      <natureOfPayment>N/A</natureOfPayment>
    </securitiesToBeSold>
    <nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</nothingToReportFlagOnSecuritiesSoldInPast3Months>
    <remarks>OrbiMed Israel BioFund GP Limited Partnership is the general partner of OrbiMed Israel Partners Limited Partnership. OrbiMed Israel GP Ltd. is the general partner of OrbiMed Israel BioFund GP Limited Partnership.</remarks>
    <noticeSignature>
      <noticeDate>09/12/2024</noticeDate>
      <signature>/s/ Douglas Coon, CCO, OrbiMed Israel GP Ltd., general partner of the general partner of OrbiMed Israel Partners Limited Partnership</signature>
    </noticeSignature>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
